You are here

P&T® Journal contents for September 2005


With the proliferation of e-mail alerts, “chronic fatigue” takes on a whole new meaning.
Nancy L. Greengold, MD, MBA
Dr. Goldenberg discusses ramelteon (Rozerem™) for insomnia, a lidocaine–tetracaine patch (Synera™) for local dermal analgesia, and insulin detemir (Levemir®), a short-acting insulin analogue for type-1 and type-2 diabetes.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Some new therapies include tesaglitazar for insulin-resistant nondiabetic patients; vildagliptin, exenatide, metaglidasen, insulin glargine, pioglitazone, and rimonabant for problems associated with type-2 diabetes; inhaled insulin powder for type-1 diabetes; and pregabalin for reducing pain in diabetic peripheral neuropathy.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Continuing Education Credit
The authors present an overview of some pharmacological and nonpharmacological modalities for treating the widespread public health problem of back pain, a major cause of disability in the U.S.
Roy R. Reeves, DO, PhD, Terrel L. Algood, RPh, and P. Melonee Wise, RPh


David Nash, MD, MBA, describes the concept of benefit-based co-payments, designed so that sick patients would pay less for medications than patients who use medications to prevent illness.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses ways to reduce the potential for tricks of the mind, including illusions, faulty memory, and unconscious actions, all of which can affect the performance of health care professionals.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas explains the recent voluntary guidelines issued by PhRMA on direct-to-consumer drug advertising.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Acamprosate calcium (Campral®) may help in maintaining abstinence from alcohol.
Daniela Espino, PharmD, and Martin P. Cruz, PharmD, CGP